[Fall in the levels of circulating lymphoblasts caused by intravenous administration of the A50 monoclonal antibody in a patient with acute T-cell lymphoblastic leukemia. A step in the demonstration of serotherapy with monoclonal antibodies].
In an 8-year-old boy with acute lymphoblastic leukaemia not previously treated intravenous administration of a single 8 mg dose of a monoclonal antibody that recognizes an epitope restricted to the surface of mature T-cells resulted, within 20 hours, in a fall in circulating lymphoblasts from 200 000 to 70 000. No adverse clinical or biological reaction was detected and no antigenic modulation occurred at lymphoblast surface. This observation constitutes a first step in the complex development of effective serotherapy for malignant diseases, using monoclonal antibodies.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology; D002675:Child, Preschool; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D007945:Leukemia, Lymphoid / Q000628:therapy*; D007958:Leukocyte Count; D008214:Lymphocytes / Q000187:drug effects*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D013997:Time Factors
D000911:Antibodies, Monoclonal
Chute du taux des lymphoblastes circulants par administration intra-veineuse de l'anticorps monoclonal A50 chez un malade ayant une leucémie aiguë lymphoblastique à cellules T. Une étape dans la mise au point de la sérothérapie par les anticorps monoclonaux.